Ezekiel Emanuel : « Qu’est-ce qu’un bon système de santé ? »

Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer

“…For example, most drugs used to treat and cure acute lymphoblastic leukemia, the most common childhood cancer with a survival rate approximating 90%, have been in use for more than 50 years; yet over the past decade, 8 of the 10 drugs most commonly used in curative acute lymphoblastic leukemia regimens have temporarily been unavailable. 37 In 2011, Ezekiel Emanuel, MD, PhD, 38 noted the stark incongruity that expensive, brand-name chemotherapeutics that extend patients' lives by a few months at a cost of $90 000 per patient are never scarce, whereas older, curative agents with a cost of as little as $3 per dose are. Since 2011, cancer drug prices have further increased.…”

“…27 The rationale for creating an EML in high-income countries, such as the United States, is supported by shortages of critical and lifesaving medications as well as budgetary constraints. 44 In the longterm, an EML would also be more cost effective, 38 since the annual cost of managing US drug shortages has been estimated as high as $416 million. 37 For all these reasons, US, Canadian, and Australian commentators have advocated that each of these countries establish an EML.…”

“…In 2011, Ezekiel Emanuel, MD, PhD, noted the stark incongruity that expensive, brand-name chemotherapeutics that extend patients’ lives by a few months at a cost of $90 000 per patient are never scarce, whereas older, curative agents with a cost of as little as $3 per dose are. Since 2011, cancer drug prices have further increased.…”